QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 12 February 2003
doi: 10.1242/jcs.00312

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jcs.00312v1 116/7/1305    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seelenmeyer, C. Articles by Nickel, W. Search for Related Content PubMed PubMed Citation Articles by Seelenmeyer, C. Articles by Nickel, W. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Medline Plus Health Information Cancer Social Bookmarking                         What's this?

The cancer antigen CA125 represents a novel counter receptor for galectin-1

Claudia Seelenmeyer^*, Sabine Wegehingel^*, Johannes Lechner and Walter Nickel

Biochemie-Zentrum Heidelberg (BZH), Im Neuenheimer Feld 328, 69120 Heidelberg, Germany

Author for correspondence (e-mail: walter.nickel{at}urz.uni-heidelberg.de)

Accepted 9 December 2002

CA125 is an ovarian cancer antigen whose recently elucidated primary structure suggests that CA125 is a giant mucin-like glycoprotein present on the cell surface of tumor cells. Here, we establish a functional link between CA125 and ß-galactoside-binding, cell-surface lectins, which are components of the extracellular matrix implicated in the regulation of cell adhesion, apoptosis, cell proliferation and tumor progression. On the basis of mass spectrometry and immunological analyses, we find that CA125 is a counter receptor for galectin-1, as both soluble and membrane-associated fragments of CA125 derived from HeLa cell lysates are shown to bind specifically to human galectin-1 with high efficiency. This interaction is demonstrated (1) to depend on ß-galactose-terminated, O-linked oligosaccharide chains of CA125, (2) to be preferential for galectin-1 versus galectin-3 and (3) to be regulated by the cellular background in which CA125 is expressed. Despite lacking a conventional signal peptide, a CA125 C-terminal fragment of 1148 amino acids, representing less than 10% of the full-length protein, retains the ability to integrate into secretory membranes such as the endoplasmic reticulum (ER) and the Golgi, and is targeted to the plasma membrane by conventional secretory transport. As demonstrated by a novel assay that reconstitutes non-conventional secretion of galectin-1 based on fluorescence-activated cell sorting (FACS), we find that tumor-derived HeLa cells expressing endogenous CA125 present more than ten times as much galectin-1 on their surface compared with non-tumor-derived, CA125-deficient CHO cells. Intriguingly, both the galectin-1 expression level and the cell-surface binding capacity for galectin-1 are shown to be similar in CHO and HeLa cells, suggesting that CA125 might be a factor involved in the regulation of galectin-1 export to the cell surface.

Key words: CA125, Galectin, Counter receptor, Nonclassical export, Cell-surface expression, Tumor antigen

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Camby, M. Le Mercier, F. Lefranc, and R. Kiss Galectin-1: a small protein with major functions Glycobiology, November 1, 2006; 16(11): 137R - 157R. [Abstract] [Full Text] [PDF]

				C. Seelenmeyer, S. Wegehingel, I. Tews, M. Kunzler, M. Aebi, and W. Nickel Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1 J. Cell Biol., October 24, 2005; 171(2): 373 - 381. [Abstract] [Full Text] [PDF]

				M. M. Jankovic and B. S. Tapuskovic Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen Hum. Reprod., September 1, 2005; 20(9): 2632 - 2638. [Abstract] [Full Text] [PDF]

				T. E Spencer, G. A Johnson, F. W Bazer, and R. C Burghardt Implantation mechanisms: insights from the sheep Reproduction, December 1, 2004; 128(6): 657 - 668. [Abstract] [Full Text] [PDF]

				A. Rump, Y. Morikawa, M. Tanaka, S. Minami, N. Umesaki, M. Takeuchi, and A. Miyajima Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion J. Biol. Chem., March 5, 2004; 279(10): 9190 - 9198. [Abstract] [Full Text] [PDF]